Amyloidosis, Blood and Marrow Transplant (BMT)
Conditions
Brief summary
To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.
Detailed description
To learn about the use of high dose chemotherapy followed by transplantation using peripheral blood stem cells.
Interventions
Sponsors
Stanford University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Primary amyloidosis 2\. Age \< 75 years. 3\. Patients must have their pathology reviewed and the diagnosis confirmed at Stanford University Medical Center. 4\. Patients who have undergone bone marrow transplantation previously will not be eligible. 5\. Patients must have a Karnofsky performance status greater than 70%. 6\. Patients must have a serum creatinine less than 2 mg/dl or creatinine clearance greater than 30 ml/min, bilirubin less than 2 mg/dl, transaminases less than two times normal, left ventricular ejection fraction \>45% on echocardiography, cardiac index \> 1.8 liters/min/m\^2 and pulmonary function tests demonstrating FEV1 and DLCO \> 60%. 7\. Patients must be HIV negative. 8\. Pregnant or lactating women will not be eligible to participate. 9\. Patients must provide signed informed consent. 10\. Patients with multiple myeloma and amyloid are eligible.
Exclusion criteria
1. prior blood or marrow transplant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis | — |
Countries
United States
Outcome results
None listed